244 related articles for article (PubMed ID: 29637702)
1. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
[TBL] [Abstract][Full Text] [Related]
2. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
3. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.
Ang WH; Khalaila I; Allardyce CS; Juillerat-Jeanneret L; Dyson PJ
J Am Chem Soc; 2005 Feb; 127(5):1382-3. PubMed ID: 15686364
[TBL] [Abstract][Full Text] [Related]
4. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.
Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ
Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763
[TBL] [Abstract][Full Text] [Related]
5. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
[TBL] [Abstract][Full Text] [Related]
6. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of platinum-ethacrynic acid conjugates in the treatment of mesothelioma.
Zanellato I; Bonarrigo I; Sardi M; Alessio M; Gabano E; Ravera M; Osella D
ChemMedChem; 2011 Dec; 6(12):2287-93. PubMed ID: 22025407
[TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
9. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
Lee VEY; Chin CF; Ang WH
Dalton Trans; 2019 Jun; 48(21):7388-7393. PubMed ID: 30957798
[TBL] [Abstract][Full Text] [Related]
10. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
11. Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation.
Parker LJ; Italiano LC; Morton CJ; Hancock NC; Ascher DB; Aitken JB; Harris HH; Campomanes P; Rothlisberger U; De Luca A; Lo Bello M; Ang WH; Dyson PJ; Parker MW
Chemistry; 2011 Jul; 17(28):7806-16. PubMed ID: 21681839
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
13. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
15. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
[TBL] [Abstract][Full Text] [Related]
17. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
18. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
19. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
[TBL] [Abstract][Full Text] [Related]
20. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
